Wang Liming, Liu Shiguang, Quarles L Darryl, Spurney Robert F
Division of Nephrology, Department of Medicine, Duke University, Durham, North Carolina, USA.
Am J Physiol Endocrinol Metab. 2005 Apr;288(4):E826-34. doi: 10.1152/ajpendo.00422.2004. Epub 2004 Dec 7.
To investigate the role of G protein-coupled receptor kinases (GRKs) in regulating bone formation in vivo, we overexpressed the potent G protein-coupled receptor (GPCR) regulator GRK2 in osteoblasts, using the osteocalcin gene-2 promoter to target expression to osteoblastic cells. Using the parathyroid hormone (PTH) receptor as a model system, we found that overexpression of GRK2 in osteoblasts attenuated PTH-induced cAMP generation by mouse calvaria ex vivo. This decrease in GPCR responsiveness was associated with a reduction in bone mineral density (BMD) in transgenic (TG) mice compared with non-TG littermate controls. The decrease in BMD was most prominent in trabecular-rich lumbar spine and was not observed in cortical bone of the femoral shaft. Quantitative computed tomography indicated that the loss of trabecular bone was due to a decrease in trabecular thickness, with little change in trabecular number. Histomorphometric analyses confirmed the decrease in trabecular bone volume and demonstrated reduced bone remodeling, as evidenced by a decrease in osteoblast numbers and osteoblast-mediated bone formation. Osteoclastic activity also appeared to be reduced because urinary excretion of the osteoclastic activity marker deoxypyridinoline was decreased in TG mice compared with control animals. Consistent with reduced coupling of osteoblast-mediated bone formation to osteoclastic bone resorption, mRNA levels of both osteoprotegrin and receptor activator of NF-kappaB ligand were altered in calvaria of TG mice in a pattern that would promote a low rate of bone remodeling. Taken together, these data suggest that enhancing GRK2 activity and consequently reducing GPCR activity in osteoblasts produces a low bone-turnover state that reduces bone mass.
为了研究G蛋白偶联受体激酶(GRKs)在体内调节骨形成中的作用,我们利用骨钙素基因-2启动子将强效G蛋白偶联受体(GPCR)调节剂GRK2在成骨细胞中过表达,从而将表达靶向至成骨细胞。以甲状旁腺激素(PTH)受体作为模型系统,我们发现成骨细胞中GRK2的过表达在体外减弱了PTH诱导的小鼠颅骨cAMP生成。与非转基因同窝对照相比,转基因(TG)小鼠中GPCR反应性的这种降低与骨矿物质密度(BMD)的降低有关。BMD的降低在富含小梁的腰椎中最为明显,而在股骨干的皮质骨中未观察到。定量计算机断层扫描表明,小梁骨的丢失是由于小梁厚度的减小,小梁数量变化不大。组织形态计量学分析证实了小梁骨体积的减少,并表明骨重塑减少,这可通过成骨细胞数量和成骨细胞介导的骨形成的减少来证明。破骨细胞活性似乎也降低了,因为与对照动物相比,TG小鼠中破骨细胞活性标志物脱氧吡啶啉的尿排泄减少。与成骨细胞介导的骨形成与破骨细胞骨吸收的偶联减少一致,TG小鼠颅骨中骨保护素和NF-κB配体受体激活剂的mRNA水平均发生改变,其模式将促进低骨重塑率。综上所述,这些数据表明,增强GRK2活性并因此降低成骨细胞中的GPCR活性会产生降低骨量的低骨转换状态。